Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Inclusion Criteria:

Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's Disease (WHO criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant
Must have received first line chemotherapy. No upper limit to number of prior therapies
Evaluable Disease
Age >18 years
Eastern Cooperative Oncology Group (ECOG) performance status <2
Life expectancy of greater than 3 months
Patients must have adequate organ and marrow function
Adequate Contraception
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Prior Therapy

Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 7 days prior to the start of the study drugs
No monoclonal antibody within 3 months unless evidence of progression
Patients may not be receiving any other investigational agents
Patients with known central nervous system metastases, including lymphomatous meningitis
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, niacinamide or etoposide
Uncontrolled intercurrent illness
Pregnant women
Nursing women
Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years
Patient is known to be Human Immunodeficiency Virus (HIV)-positive
Active Hepatitis A, Hepatitis B, or Hepatitis C infection
Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs